HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

538.000

+5.0000.94%

Volume:561.82K

Turnover:301.87M

Market Cap:128.58B

PE:-278.39

High:545.000

Open:541.500

Low:527.500

Close:533.000

52wk High:581.000

52wk Low:339.600

Shares:239.00M

HK Float Shares:177.00M

Volume Ratio:0.80

T/O Rate:0.32%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.933

ROE:2.92%

ROA:0.03%

PB:20.66

PE(LYR):-278.39

PS:52.85

Loading ...

Overview Company News Filings

Sichuan Kelun-Biotech Wins China IND Nod for Cancer Therapy

MT Newswires Live

SKB BIO Receives NMPA Approval for Investigational New Drug Application of SKB118

SKB BIO Secures NMPA Green Light for PD-1/VEGF Bispecific Antibody SKB118; Crescent Biopharma Collaboration Advances Global Development

Bulletin Express

Kelun-Biotech says China regulator clears SKB118 clinical trial application

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Receives Nmpa Approval for Ind Application for Skb118 (Cr-001) for Advanced Solid Tumors

THOMSON REUTERS

SKB Biopharma's Application for New Indication of Tumor Drug Accepted in China

MT Newswires Live

the Snda for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Pembrolizumab as First‑Line Treatment for Pd-L1-Positive Nsclc Accepted for Review by Nmpa

THOMSON REUTERS

SKB BIO's Core TROP2 ADC Therapy Sac-TMT Gains NMPA Acceptance for New Indication Application

Kelun-Biotech sac-TMT plus Keytruda NSCLC application accepted for review by China regulator

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Nmpa Accepts New Indication Application for Sacituzumab Tirumotecan (Sac-TMT)

THOMSON REUTERS

3 Asian Stocks That May Be Undervalued In May 2026

Simply Wall St.

SKB BIO Shares Rise Nearly 3% in Late Trading as Three Studies Selected for Oral Presentation at 2026 ASCO Meeting

Kelun-Biotech to present three studies in oral sessions at 2026 ASCO meeting

Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 Asco Annual Meeting

THOMSON REUTERS

SKB BIO Updates Articles of Association: 233.19 Million-Share Structure, 11-Member Board and Cash-First Dividend Policy Confirmed

Bulletin Express

Kelun-Biotech converts 8.21 million Domestic and Unlisted Foreign shares; H-share free float lifts to 73.32%

Bulletin Express

SKB BIO-B Completes Full Circulation of H Shares

Kelun-Biotech converts 8,214,278 shares into H shares for Hong Kong listing

Assessing Sichuan Kelun Biotech (SEHK:6990) Valuation After Positive Phase II Sacituzumab Tirumotecan Data

Simply Wall St.

科伦博泰2025年度核心业绩与业务综述：营收稳步增长，研发投入持续加大

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/06990/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"SKB BIO","latestPrice":538,"timestamp":1787299688008,"preClose":533,"halted":0,"volume":561824,"delay":0,"changeRate":0.009380863039399626,"floatShares":177000000,"shares":239000000,"eps":-1.932537526792364,"marketStatus":"Not Yet Opened","change":5,"latestTime":"08-21 16:08:08","open":541.5,"high":545,"low":527.5,"amount":301866735,"amplitude":0.032833,"askPrice":538,"askSize":1100,"bidPrice":537.5,"bidSize":1100,"shortable":3,"etf":0,"ttmEps":0.756090450252832,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":533,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.7972975352660581,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":177000000,"roa":"0.03%","roe":"2.92%","lyrEps":-1.932538,"volumeRatio":0.7972975352660581,"shares":239000000,"dividePrice":0,"high":545,"amplitude":0.032833,"preClose":533,"low":527.5,"week52Low":339.6,"pbRate":"20.66","psRate":"52.85","week52High":581,"institutionHeld":0,"latestPrice":538,"eps":-1.932537526792364,"divideRate":0,"volume":561824,"delay":0,"ttmEps":0.756090450252832,"open":541.5,"prevYearClose":392.2,"prevWeekClose":538,"prevMonthClose":483.8,"prevQuarterClose":436.2,"fiveDayClose":520.5,"twentyDayClose":514,"sixtyDayClose":474},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2026-08-17","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1786930200000,"name":null,"time":"","dateTimestamp":1786896000000,"actualEps":null},{"market":"HK","date":"2026-03-23","symbol":"06990","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-18","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755480600000,"name":null,"time":"","dateTimestamp":1755446400000,"actualEps":null},{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"Post-Mkt","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"Post-Mkt","dateTimestamp":1723996800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":21,"updateTime":1786636800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2026-08-21","current":711.261842,"percent":0.998696,"low":-351.800852,"twenty":-236.676246,"median":-135.748112,"eighty":-53.902639,"high":737.230287,"avg":-137.360118,"sd":103.774207,"marketCap":128594895322},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200},{"date":"2025-04-25","current":-235.137362,"twenty":-160.624501,"median":-68.953584,"eighty":-45.131919,"marketCap":66771338400},{"date":"2025-05-02","current":-274.570331,"twenty":-161.195254,"median":-69.468586,"eighty":-45.197413,"marketCap":78134738400},{"date":"2025-05-09","current":-249.374354,"twenty":-161.514906,"median":-70.050704,"eighty":-45.202208,"marketCap":71462875059},{"date":"2025-05-16","current":-247.507619,"twenty":-162.87029,"median":-70.732965,"eighty":-45.217068,"marketCap":71507400214},{"date":"2025-05-23","current":-244.618313,"twenty":-163.824551,"median":-71.32983,"eighty":-45.58151,"marketCap":70884048033},{"date":"2025-05-30","current":-244.159494,"twenty":-165.025774,"median":-71.669987,"eighty":-45.601984,"marketCap":71062148656},{"date":"2025-06-06","current":-258.187076,"twenty":-166.004403,"median":-72.203519,"eighty":-46.006494,"marketCap":75336563613},{"date":"2025-06-13","current":-271.678883,"twenty":-167.701589,"median":-72.488214,"eighty":-46.133909,"marketCap":79304691313},{"date":"2025-06-20","current":-252.757485,"twenty":-168.349452,"median":-72.789206,"eighty":-46.315126,"marketCap":73636805593},{"date":"2025-06-27","current":-255.806605,"twenty":-169.647858,"median":-73.569836,"eighty":-46.457129,"marketCap":74733815733},{"date":"2025-07-04","current":-283.173205,"twenty":-171.495185,"median":-73.869687,"eighty":-46.685504,"marketCap":82732847998},{"date":"2025-07-11","current":-266.231967,"twenty":-173.142078,"median":-74.539848,"eighty":-46.749361,"marketCap":77704884860},{"date":"2025-07-18","current":-304.526119,"twenty":-187.755426,"median":-75.01675,"eighty":-46.798833,"marketCap":88812112519},{"date":"2025-07-25","current":-289.211949,"twenty":-196.095673,"median":-75.38559,"eighty":-46.877904,"marketCap":84652615741},{"date":"2025-08-01","current":-318.351212,"twenty":-209.071662,"median":-75.715906,"eighty":-46.908544,"marketCap":92605939250},{"date":"2025-08-08","current":-315.832709,"twenty":-214.487876,"median":-76.34536,"eighty":-47.149906,"marketCap":92103142937},{"date":"2025-08-15","current":-340.637946,"twenty":-221.73884,"median":-77.157567,"eighty":-47.354138,"marketCap":99188000086},{"date":"2025-08-22","current":-135.707825,"twenty":-221.73884,"median":-78.335478,"eighty":-47.421279,"marketCap":106638527281},{"date":"2025-08-29","current":-131.473703,"twenty":-217.466422,"median":-78.819337,"eighty":-47.438439,"marketCap":103804584421},{"date":"2025-09-05","current":-151.82862,"twenty":-215.82299,"median":-80.340969,"eighty":-47.449348,"marketCap":119756940196},{"date":"2025-09-12","current":-146.494298,"twenty":-214.791029,"median":-81.555855,"eighty":-47.474394,"marketCap":115757424063},{"date":"2025-09-19","current":-147.466634,"twenty":-214.487876,"median":-85.53437,"eighty":-47.73502,"marketCap":116443055400},{"date":"2025-09-26","current":-143.954691,"twenty":-214.295448,"median":-89.950081,"eighty":-47.938811,"marketCap":113375018127},{"date":"2025-10-03","current":-165.853778,"twenty":-213.463042,"median":-128.34687,"eighty":-48.070155,"marketCap":130933921593},{"date":"2025-10-10","current":-144.531455,"twenty":-212.219938,"median":-131.729362,"eighty":-48.217901,"marketCap":113934664453},{"date":"2025-10-17","current":-135.703716,"twenty":-210.108236,"median":-132.867642,"eighty":-48.374971,"marketCap":106892448189},{"date":"2025-10-24","current":-129.499037,"twenty":-207.014216,"median":-133.546653,"eighty":-48.434282,"marketCap":102042180034},{"date":"2025-10-31","current":-132.379263,"twenty":-204.550971,"median":-132.326202,"eighty":-48.483234,"marketCap":104467314112},{"date":"2025-11-07","current":-120.930715,"twenty":-203.710245,"median":-131.985022,"eighty":-48.610423,"marketCap":95373061321},{"date":"2025-11-14","current":-137.099974,"twenty":-201.138492,"median":-131.729362,"eighty":-48.622244,"marketCap":108431475585},{"date":"2025-11-21","current":-125.836792,"twenty":-194.360264,"median":-130.233026,"eighty":-48.651606,"marketCap":99477134375},{"date":"2025-11-28","current":-134.139839,"twenty":-194.090443,"median":-131.64896,"eighty":-48.675637,"marketCap":106426076251},{"date":"2025-12-05","current":-134.965867,"twenty":-192.863217,"median":-131.473703,"eighty":-48.751223,"marketCap":107265545740},{"date":"2025-12-12","current":-128.449432,"twenty":-188.527876,"median":-130.526276,"eighty":-48.814858,"marketCap":102275366003},{"date":"2025-12-19","current":-122.479247,"twenty":-187.446049,"median":-129.499037,"eighty":-48.911385,"marketCap":97751558204},{"date":"2025-12-24","current":-122.098928,"twenty":-187.290368,"median":-128.758533,"eighty":-48.913338,"marketCap":97751558204},{"date":"2026-01-02","current":-116.223952,"twenty":-179.729041,"median":-128.478737,"eighty":-49.104524,"marketCap":93414299181},{"date":"2026-01-09","current":-137.872108,"twenty":-173.799059,"median":-128.508043,"eighty":-49.251224,"marketCap":111089795631},{"date":"2026-01-16","current":-136.67551,"twenty":-173.152374,"median":-129.252083,"eighty":-49.296233,"marketCap":110483512112},{"date":"2026-01-23","current":-124.044288,"twenty":-172.874196,"median":-128.511935,"eighty":-49.590244,"marketCap":100176692282},{"date":"2026-01-30","current":-119.398299,"twenty":-172.654145,"median":-128.43808,"eighty":-50.08289,"marketCap":96865451522},{"date":"2026-02-06","current":-121.3325,"twenty":-172.20913,"median":-127.906249,"eighty":-50.304899,"marketCap":98684302080},{"date":"2026-02-13","current":-119.328264,"twenty":-171.604872,"median":-127.229577,"eighty":-50.349599,"marketCap":97611646623},{"date":"2026-02-20","current":-118.929435,"twenty":-171.385498,"median":-126.777731,"eighty":-50.372821,"marketCap":97145274685},{"date":"2026-02-27","current":-109.393801,"twenty":-170.608939,"median":-126.362178,"eighty":-50.420375,"marketCap":90336244390},{"date":"2026-03-06","current":-109.941252,"twenty":-169.952459,"median":-125.237252,"eighty":-50.5225,"marketCap":90056421227},{"date":"2026-03-13","current":-111.874188,"twenty":-169.826622,"median":-125.028422,"eighty":-50.583009,"marketCap":92061820561},{"date":"2026-03-20","current":-118.784792,"twenty":-169.647858,"median":-124.510593,"eighty":-50.752344,"marketCap":97378460654},{"date":"2026-03-27","current":-246.717525,"twenty":-170.608939,"median":-124.791344,"eighty":-50.880899,"marketCap":106705913600},{"date":"2026-04-02","current":-270.1664,"twenty":-172.638036,"median":-125.053164,"eighty":-50.929189,"marketCap":117409151000},{"date":"2026-04-10","current":-262.507699,"twenty":-173.162671,"median":-125.237252,"eighty":-50.974222,"marketCap":114960698000},{"date":"2026-04-17","current":-276.768173,"twenty":-188.270393,"median":-126.362178,"eighty":-51.053793,"marketCap":121256720000},{"date":"2026-04-24","current":-263.25072,"twenty":-199.457552,"median":-126.777731,"eighty":-51.109685,"marketCap":115341038016},{"date":"2026-04-30","current":-249.758244,"twenty":-207.783795,"median":-127.598017,"eighty":-51.131881,"marketCap":109457493848},{"date":"2026-05-08","current":-237.123047,"twenty":-214.424086,"median":-128.140667,"eighty":-51.206724,"marketCap":104280765336},{"date":"2026-05-15","current":-230.895214,"twenty":-220.549694,"median":-128.478737,"eighty":-51.422215,"marketCap":101808994065},{"date":"2026-05-22","current":-251.35436,"twenty":-225.355554,"median":-129.00513,"eighty":-51.539533,"marketCap":110576786499},{"date":"2026-05-29","current":-244.039033,"twenty":-227.151092,"median":-129.499037,"eighty":-51.775379,"marketCap":107731917678},{"date":"2026-06-05","current":-207.501784,"twenty":-227.151092,"median":-130.526276,"eighty":-51.91711,"marketCap":91735360204},{"date":"2026-06-12","current":-219.148588,"twenty":-226.740676,"median":-131.473703,"eighty":-52.267792,"marketCap":96818814328},{"date":"2026-06-18","current":-218.939992,"twenty":-226.404961,"median":-131.824218,"eighty":-52.561632,"marketCap":96958725910},{"date":"2026-06-26","current":-221.178526,"twenty":-225.594566,"median":-132.326202,"eighty":-52.73121,"marketCap":97471735042},{"date":"2026-07-03","current":-263.841103,"twenty":-227.197711,"median":-132.771691,"eighty":-52.93717,"marketCap":116359798531},{"date":"2026-07-10","current":-273.42961,"twenty":-228.864297,"median":-133.50718,"eighty":-53.148078,"marketCap":120440552988},{"date":"2026-07-17","current":-263.005613,"twenty":-229.666754,"median":-134.182751,"eighty":-53.480935,"marketCap":116261258521},{"date":"2026-07-24","current":-277.867014,"twenty":-230.754675,"median":-134.677954,"eighty":-54.022455,"marketCap":122858320066},{"date":"2026-07-31","current":-261.04507,"twenty":-231.704791,"median":-134.965867,"eighty":-54.274788,"marketCap":115639796202},{"date":"2026-08-07","current":-290.535115,"twenty":-235.013451,"median":-135.70577,"eighty":-54.298503,"marketCap":128953431275},{"date":"2026-08-14","current":-279.9487,"twenty":-236.676246,"median":-136.101797,"eighty":-54.329175,"marketCap":124411975864},{"date":"2026-08-21","current":729.337059,"twenty":-236.676246,"median":-135.748112,"eighty":-53.902639,"marketCap":128594895322}],"updateTime":1787507722266},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635227068","title":"Sichuan Kelun-Biotech Wins China IND Nod for Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2635227068","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635227068?lang=en_us&edition=fundamental","pubTime":"2026-05-13 09:57","pubTimestamp":1778637426,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  received approval from China's National Medical Products Administration for the investigational new drug application of SKB118, according to a Wednesday Hong Kong bourse filing.The company said the PD-1/VEGF bispecific antibody is intended for the treatment of advanced solid tumors.The approval clears the company to begin clinical trials for the drug candidate in China, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","BK4581","BK1161","BK4585","XBI","06990","BK4588","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158310498","title":"SKB BIO Receives NMPA Approval for Investigational New Drug Application of SKB118","url":"https://stock-news.laohu8.com/highlight/detail?id=1158310498","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158310498?lang=en_us&edition=fundamental","pubTime":"2026-05-13 08:04","pubTimestamp":1778630686,"startTime":"0","endTime":"0","summary":"SKB BIO (06990) has announced that it has received a clinical trial notification from the Center for Drug Evaluation of the National Medical Products Administration. The notification grants approval...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","LU0196878994.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162503034","title":"SKB BIO Secures NMPA Green Light for PD-1/VEGF Bispecific Antibody SKB118; Crescent Biopharma Collaboration Advances Global Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1162503034","media":"Bulletin Express","labels":["corporation","productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162503034?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:43","pubTimestamp":1778629386,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO; 06990) has obtained Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) for SKB118...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635922949","title":"Kelun-Biotech says China regulator clears SKB118 clinical trial application","url":"https://stock-news.laohu8.com/highlight/detail?id=2635922949","media":"Reuters","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635922949?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:32","pubTimestamp":1778628733,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical received China NMPA clearance for an IND to start clinical trials of PD-1xVEGF bispecific antibody SKB118  in advanced solid tumors.Crescent Biopharma granted Kelun-Biotech exclusive rights in Greater China to develop, manufacture, and commercialize SKB118 under a strategic cooperation reached in December 2025.Crescent previously secured US FDA IND clearance in January 2026 to launch global Phase 1/2 ASCEND study in locally advanced or metastatic solid tumors, with planned enrollment of 290 patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Servic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL5rThZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","LU1064131003.USD","LU1934453819.USD","06990","BK0239","LU0196878994.USD","BK1161","LU2148510915.USD","LU1979443071.USD","LU1064130708.USD","002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635229126","title":"Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Receives Nmpa Approval for Ind Application for Skb118 (Cr-001) for Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2635229126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635229126?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:32","pubTimestamp":1778628724,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P1KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06990","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633945936","title":"SKB Biopharma's Application for New Indication of Tumor Drug Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2633945936","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633945936?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:40","pubTimestamp":1778244014,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical's  new indication application for sacituzumab tirumotecan was accepted for review by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The application is for the drug in combination with pembrolizumab as first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","06990","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633437933","title":"the Snda for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Pembrolizumab as First‑Line Treatment for Pd-L1-Positive Nsclc Accepted for Review by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2633437933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633437933?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:40","pubTimestamp":1778236827,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA4WS7GY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","06990","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150179988","title":"SKB BIO's Core TROP2 ADC Therapy Sac-TMT Gains NMPA Acceptance for New Indication Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1150179988","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150179988?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:22","pubTimestamp":1778235723,"startTime":"0","endTime":"0","summary":"Kelun-Bota Biopharma (06990) has announced that a new supplemental New Drug Application (sNDA) for its TROP2-targeting antibody-drug conjugate (ADC), sacituzumab govitecan (sac-TMT, also known as...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK4080","LU0196878994.USD","IPOS","BK4231","BK1161","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633434014","title":"Kelun-Biotech sac-TMT plus Keytruda NSCLC application accepted for review by China regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2633434014","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633434014?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:14","pubTimestamp":1778235247,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech new indication application for TROP2 ADC sacituzumab tirumotecan  with Merck’s pembrolizumab accepted for review by China NMPA.Filing targets first-line treatment of adult patients with locally advanced or metastatic NSCLC with PD-L1 TPS ≥1%, EGFR-negative, ALK-negative.CDE placed application into priority review and approval process, potentially accelerating clearance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL7gXcRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","002422","BK0239","BK0060","06990","LU2148510915.USD","LU1064130708.USD","LU1934453819.USD","BK1161","LU0196878994.USD","LU1979443071.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633343406","title":"Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Nmpa Accepts New Indication Application for Sacituzumab Tirumotecan (Sac-TMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633343406","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633343406?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:14","pubTimestamp":1778235240,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L0D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","06990","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632947746","title":"3 Asian Stocks That May Be Undervalued In May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2632947746","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632947746?lang=en_us&edition=fundamental","pubTime":"2026-05-01 12:08","pubTimestamp":1777608485,"startTime":"0","endTime":"0","summary":"As global markets navigate geopolitical tensions and economic shifts, Asian equities have shown resilience, with some indices stabilizing amid mixed performances across major regions. In this environment of cautious optimism and strategic positioning, identifying undervalued stocks can offer potential opportunities for investors seeking to capitalize on market inefficiencies.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9621091-choice2-main-header/1585186855318","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9621091-choice2-main-header/1585186855318"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/tw/tech/twse-2301/lite-on-technology-shares/news/3-asian-stocks-that-may-be-undervalued-in-may-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/tw/tech/twse-2301/lite-on-technology-shares/news/3-asian-stocks-that-may-be-undervalued-in-may-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06990","BK1161","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154953853","title":"SKB BIO Shares Rise Nearly 3% in Late Trading as Three Studies Selected for Oral Presentation at 2026 ASCO Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1154953853","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154953853?lang=en_us&edition=fundamental","pubTime":"2026-04-24 15:40","pubTimestamp":1777016441,"startTime":"0","endTime":"0","summary":"SKB BIO (06990) saw its shares climb nearly 3% in late trading. At the time of writing, the stock was up 2.24%, trading at HK$475, with a turnover of HK$235 million. The 2026 American Society of...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK4588","06990","BK1161","LU0196878994.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629062970","title":"Kelun-Biotech to present three studies in oral sessions at 2026 ASCO meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629062970","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629062970?lang=en_us&edition=fundamental","pubTime":"2026-04-22 08:54","pubTimestamp":1776819261,"startTime":"0","endTime":"0","summary":"Kelun-Biotech will present three oral clinical study readouts at 2026 ASCO Annual Meeting in Chicago, running May 29 to June 2.Data from Phase III OptiTROP-Lung05 for TROP2 ADC sacituzumab tirumotecan with pembrolizumab in first-line PD-L1-positive advanced NSCLC is scheduled May 29.Results from pivotal Phase II study of RET inhibitor lunbotinib in RET fusion-positive advanced NSCLC will be delivered May 29.First-in-human study results for ADC candidate SKB500 in advanced solid tumors will be presented June 2.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL5cT0pv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1979443071.USD","LU1064130708.USD","BK0239","LU0196878994.USD","002422","BK0060","LU1064131003.USD","LU2148510915.USD","06990","LU1934453819.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629062950","title":"Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 Asco Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629062950","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629062950?lang=en_us&edition=fundamental","pubTime":"2026-04-22 08:54","pubTimestamp":1776819245,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA3QMLMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0196878994.USD","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159754311","title":"SKB BIO Updates Articles of Association: 233.19 Million-Share Structure, 11-Member Board and Cash-First Dividend Policy Confirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=1159754311","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159754311?lang=en_us&edition=fundamental","pubTime":"2026-04-17 20:05","pubTimestamp":1776427551,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (abbreviation: SKB BIO) released its revised Articles of Association, which will apply following the company’s H-share listing on the Hong Kong Stock...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180754950","title":"Kelun-Biotech converts 8.21 million Domestic and Unlisted Foreign shares; H-share free float lifts to 73.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180754950","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180754950?lang=en_us&edition=fundamental","pubTime":"2026-04-17 20:05","pubTimestamp":1776427540,"startTime":"0","endTime":"0","summary":"On 17 April 2026, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) announced the completion of its H-share full-circulation programme, converting 8.21 million Domestic and Unlisted...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154806895","title":"SKB BIO-B Completes Full Circulation of H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1154806895","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154806895?lang=en_us&edition=fundamental","pubTime":"2026-04-17 19:54","pubTimestamp":1776426862,"startTime":"0","endTime":"0","summary":"SKB BIO-B (06990) announced that approximately 8.2143 million domestic shares and non-listed foreign shares were converted on April 17, 2026. The converted H shares will commence trading on the Hong Kong Stock Exchange starting at 9:00 a.m. on April 20, 2026.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","06990","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628053752","title":"Kelun-Biotech converts 8,214,278 shares into H shares for Hong Kong listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2628053752","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628053752?lang=en_us&edition=fundamental","pubTime":"2026-04-17 19:50","pubTimestamp":1776426652,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech completed conversion of 8,214,278 domestic shares and unlisted foreign shares into H shares on April 17, 2026.Listing of converted H shares will start at 9:00 a.m. on April 20, 2026.Converted shares represent about 3.5% of total share capital.H shares outstanding rise to 170,984,257 from 162,769,979.Domestic shares outstanding fall to 62,201,712 from 65,773,800.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDLc9CWkX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1064131003.USD","LU1934453819.USD","BK0060","LU1064130708.USD","LU2148510915.USD","BK0239","002422","06990","LU0196878994.USD","LU1979443071.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628242784","title":"Assessing Sichuan Kelun Biotech (SEHK:6990) Valuation After Positive Phase II Sacituzumab Tirumotecan Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2628242784","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628242784?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:09","pubTimestamp":1776370157,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) is back in focus after presenting Phase II data for its TROP2 ADC sacituzumab tirumotecan with pembrolizumab in ovarian and cervical cancer at the 2026 Society of Gynecologic Oncology meeting.\nSee our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.\nThe strong Phase II data appears to sit alongside building momentum in the shares, with a 30.30% year to date share price return and a 1 year total shareholder return of 82.90% at a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/assessing-sichuan-kelun-biotech-sehk6990-valuation-after-pos","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/assessing-sichuan-kelun-biotech-sehk6990-valuation-after-pos","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","LU0196878994.USD","XBI","BK4581","DCF","06990","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116846497","title":"科伦博泰2025年度核心业绩与业务综述：营收稳步增长，研发投入持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=1116846497","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116846497?lang=en_us&edition=fundamental","pubTime":"2026-04-16 23:07","pubTimestamp":1776352067,"startTime":"0","endTime":"0","summary":"科伦博泰（SKB BIO-B）于2025年度在核心业务和研发领域实现多项突破，进一步加速由生物技术企业向具备药品研发与商业化一体化能力的生物制药企业转型。根据年度报告及相关章节内容，主要年度亮点和变化如下： 一、经营业绩与财务表现...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}